AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05698095
Drug: 5-methoxy-N,N-dimethyltryptamine succinate salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
Trial: NCT05698095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
Trial: NCT04857866
Drug: XmAb27564
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose of XmAb27564
Trial: NCT04857866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo
Trial: NCT05010174
Drug: MDR product
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation of patients previously receiving MDR product(s)
Trial: NCT06203405
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
Trial: NCT05066841
Drug: 10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks
Trial: NCT00000826
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05789732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo treatment once daily.
Trial: NCT05075876
Drug: SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application for 6 days
Trial: NCT05600218
Drug: No intervention - Observational study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real life drug evaluation
Trial: NCT04075435
Drug: high CBD/low THC sublingual solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemp derived solution to be administered sublingually twice daily.
Trial: NCT05966025
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will taken by patient in control group
Trial: NCT06023095
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06023095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05421078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active ingredient
Trial: NCT04616781
Drug: Isocaloric dextrose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink indistinguishable from ketone ester
Trial: NCT05728892
Drug: Melatonin 3 MG
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preopertive melatonin adminstration oral 0.2 mg /kg 45 min before general anaethesia.
Trial: NCT05626881
Drug: sylimarin cream
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin was manufactured with concentration of 1.4%
Trial: NCT04871334
Drug: TWP-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion Q2W for 4 weeks (28-day cycles)
Trial: NCT04844385
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy
Trial: NCT06165068
Drug: Aspirin 81Mg Ec Tab
RxNorm normalized name: ASPIRIN 81MG EC TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take aspirin 81 mg per day.
Trial: NCT05066620
Drug: Chinese herbal medicine FYTF-919
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
Trial: NCT06534021
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be given one dose of placebo. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
Trial: NCT06485271
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment
Trial: NCT05086692
Drug: MDNA11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
Trial: NCT06663943
Drug: CM313 (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
Trial: NCT06663943
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group receive azathioprine in combination with steroid therapy.
Trial: NCT05667298
Drug: Adjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible.
Trial: NCT04926753
Drug: 5-Fluorouracil, Cisplatin, Toripalimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
Trial: NCT06583291
Drug: Allogeneic dopaminergic neural precursor cell(iDAP)
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral implantation
Trial: NCT06583551
Drug: Myorel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacarbamol (380mg), paracetamol (300mg)
Trial: NCT06583811
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.
Trial: NCT04953923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral administration
Trial: NCT05511350
Drug: TJ210001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05645627
Drug: IBI112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
Trial: NCT05645627
Drug: placebo /IBI112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
Trial: NCT06440772
Drug: Ringer's Lactate Crystalloid Solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 ml/kg ml of Ringer's Lactate is given in 10 min amongst initially tolerant fluid responders.
Trial: NCT06109428
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg
Trial: NCT06109428
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg
Trial: NCT06109428
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g
Trial: NCT05449028
Drug: H. pylori eradication scheme A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
Trial: NCT05449028
Drug: H. pylori eradication scheme B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
Trial: NCT05449028
Drug: H. pylori eradication scheme C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
Trial: NCT05449028
Drug: H. pylori eradication scheme E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
Trial: NCT06587347
Drug: Standard medical treatment (SMT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive standard antiplatelet therapy.
Trial: NCT05212259
Drug: Collagen type II (40 mg/day)
RxNorm normalized name: collagen type II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules per day
Trial: NCT05212259
Drug: Collagen type II (80mg/day)
RxNorm normalized name: collagen type II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules per day
Trial: NCT05212259
Drug: Collagen type II (120 mg/day)
RxNorm normalized name: collagen type II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules per day
Trial: NCT05212259
Drug: Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules per day
Trial: NCT05212259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules per day
Trial: NCT06504030
Drug: modified-DEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.
Trial: NCT06193538
Drug: Recombinant NV-A01 adenovirus injection
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
Trial: NCT05101187
Drug: AmBisome®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
Trial: NCT01142414
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05448001
Drug: JP-1366 20mg
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
Trial: NCT00018109
Drug: creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03160430
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsule
Trial: NCT06481995
Drug: Fibrogammin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing
Trial: NCT02001584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05575999
Drug: Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
Trial: NCT06573411
Drug: ACEI/ARB+ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
Trial: NCT04862091
Drug: ZYTIGA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYTIGA®
Trial: NCT05597020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
Trial: NCT06573164
Drug: conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use conventional medication as needed based on the patient's condition.
Trial: NCT06574347
Drug: PLB1004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive PLB1004 80mg orally once per day (QD).
Trial: NCT05397379
Drug: HEC96719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT05397379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT06271551
Drug: Active Comparator: Androgen deprivation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
Trial: NCT05809895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline intravenously (IV) Q3W
Trial: NCT05074433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06041477
Drug: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
Trial: NCT06467318
Drug: NSAID, Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
Trial: NCT06081166
Drug: Rosuvastatin Calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 40 mg
Trial: NCT06408285
Drug: TQC3927 powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC3927 is a targeted inhibitor.
Trial: NCT06408285
Drug: TQC3927 powder for inhalation placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC3927 powder for inhalation placebo contains no active substance.
Trial: NCT06211647
Drug: [177Lu]Lu-XT117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.
Trial: NCT01070290
Drug: Oxaliplatin, capecitabine or irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice or oxaliplatin, capecitabine or irinotecan
Trial: NCT05050188
Drug: H008 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
Trial: NCT05251233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
Trial: NCT04630158
Drug: SAF312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular, suspension eye drops
Trial: NCT04866134
Drug: ERAS-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERAS-007 will be administered orally as specified in Arm description.
Trial: NCT04866134
Drug: ERAS-601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERAS-601 will be administered orally as specified in Arm description.
Trial: NCT04928222
Drug: Placebo-containing MNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
Trial: NCT06571461
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: Oral
Trial: NCT04840745
Drug: CKD-841 A-1 3.75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection, subcutaneous injection
Trial: NCT04840745
Drug: CKD-841 A-1 1.88mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection, subcutaneous injection
Trial: NCT04840745
Drug: CKD-841 D 2.92mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection, subcutaneous injection
Trial: NCT04840745
Drug: Leuplin Inj. 3.75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection, subcutaneous injection
Trial: NCT05199090
Drug: MBL949
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections administered for 14 weeks
Trial: NCT05458193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet for oral use
Trial: NCT05622591
Drug: ELU001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
Trial: NCT05199090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator to MLB949
Trial: NCT04720534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calculated volume to match active treatment by sc injection
Trial: NCT05061446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
Trial: NCT05211622
Drug: 1. alpha acid lipoic - tables
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days
Trial: NCT05211622
Drug: 2. ozonated oil - mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks
Trial: NCT05383170
Drug: CyPep-1
RxNorm normalized name: Cypex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection
Trial: NCT04901884
Drug: PET/MR with 18F-FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
Trial: NCT05995444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)
Trial: NCT06349044
Drug: Oxaliplatin and Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
Trial: NCT06349044
Drug: Anti-VEGF 15mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 15mg/kg d1 iv q3w
Trial: NCT06349044
Drug: Anti-VEGF 7.5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5mg/kg d1 iv q3w
Trial: NCT05148026
Drug: Unfractionated heparin first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
Trial: NCT04819360
Drug: Botox 100 UNT Injection
RxNorm normalized name: Botox 100 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection of Botox® 100 UNT
Trial: NCT05126888
Drug: SCI-110
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
Trial: NCT05443984
Drug: JP-1366 20mg
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)